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Galectin-8 (Gal-8), a ‘tandem-repeat’-type galectin, has been described as a modulator of 
cellular functions including adhesion, spreading, growth arrest, apoptosis, pathogen recognition, 
autophagy, and immunomodulation. We have previously shown that activated leukocyte cell 
adhesion molecule (ALCAM), also known as CD166, serves as a receptor for endogenous Gal-8. 
ALCAM is a member of the immunoglobulin superfamily involved in cell-cell adhesion through 
homophilic (ALCAM-ALCAM) and heterophilic (i.e. ALCAM-CD6) interactions in different 
tissues. Here we investigated the physiologic relevance of ALCAM-Gal-8 association and 
glycosylation-dependent mechanisms governing these interactions. We found that silencing of 
ALCAM in MDA-MB-231 triple negative breast cancer cells decreases cell adhesion and 
migration onto Gal-8-coated surfaces in a glycan-dependent fashion. Remarkably, either Gal-8 or 
ALCAM silencing also disrupted cell-cell adhesion, and led to reduced tumor growth in a murine 
model of triple negative breast cancer. Moreover, structural characterization of endogenous 
ALCAM N-glycosylation showed abundant permissive structures for Gal-8 binding. Importantly, 
we also found that cell sialylation controls Gal-8-mediated cell adhesion. Altogether, these 
findings demonstrate a central role of either ALCAM or Gal-8 (or both) in controlling triple 
negative breast cancer. 
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Galectin-8 (Gal-8), an endogenous “tandem-repeat”-type galectin [1,2] with two 
carbohydrate recognition domains (CRDs), shows a complex gene regulation, and presents at 
least seven isoforms as a result of mRNA splicing [3,4]. Gal-8 has been described as a modulator 
of different cellular functions including cell adhesion and spreading [5-7], growth arrest and 
apoptosis [8], pathogen recognition [9], autophagy [10,11], and immunosuppression [12]. Gal-8 is 
one of the most widely expressed “tandem-repeat” galectins in human tissues, being detected in 
normal and tumor cells [13-16]. Of note, the level of amplification of LGALS8 (Gal-8 gene) in 
different cancer patients exceeds by far that of other common galectins like Gal-1 or Gal-3, 
particularly in breast tumors [17]. In breast cancer, and using validated and clinically relevant 
genetically engineered mouse models (GEMMs), Gal-8 was shown to be one of the five most 
frequently identified genes among fifteen tumor antigens detected in a neu transgenic mouse 
model with negative estrogen receptor [18]. Moreover, in sera from patients with breast cancer, 
Gal-8 concentrations were higher than in healthy individuals [19,20]. Importantly, Gal-8 
overexpression has been shown to transform MDCK canine kidney cells, inducing reversible 
epithelial-mesenchymal transition (EMT), and leading to larger tumors than parental cells when 
subcutaneously inoculated in immunosuppressed mice [21]. 
Upon secretion, Gal-8 has been shown to act as a matrix protein equipotent to fibronectin 
in the promotion of cell adhesion, by ligating and inducing clustering of several cell surface 
receptors, i.e. integrins [4-6,22]. For example, immobilized Gal-8 supported dose-dependent cell 
adhesion of H1299 human non-small cell lung carcinoma cells, Fao rat hepatoma cells, HeLa 
human cervical cancer cells, NIH-hIR murine fibroblasts as well as CHO-P Chinese hamster 
ovary [6,23] and human trabecular meshwork cells [24]. In glioblastoma cells, immobilized Gal-8 
promoted U373 cell migration [25], while soluble Gal-8, acting as a chemoattractant, induced the 
migration of U87 cells [26]. Accordingly, binding of metastatic lung cancer cells to Gal-8 in 
combination with fibronectin has been associated with the metastatic progression of lung 
adenocarcinoma [27]. Moreover, Gal-8 also promoted lymphatic endothelial cell adhesion and 
migration [28], and vascular endothelial cell migration [29]. Notably, Gal-8 has been reported to 
induce increased adhesion of colon cancer cells to endothelial cells [19,30], suggesting that 
moderate concentrations of Gal-8 in serum might favour dissemination of tumor cells by 
promoting their heterotypic adhesion to vascular or lymphatic endothelium. Noteworthy, and in 















osteolysis [32,33], and may also influence tumor-immune escape as it promotes expansion of 
regulatory T cells through modulation of TGF- and IL-2 signaling [12]. 
We have previously shown that activated leukocyte cell adhesion molecule (ALCAM/ 
CD166) serves as a receptor for endogenous Gal-8 in endothelial cells [29]. ALCAM, a member 
of the immunoglobulin superfamily with five extracellular immunoglobulin-like domains, 
functions as a cell-cell adhesion modulator in homophilic (ALCAM-ALCAM) and heterophilic 
(i.e. ALCAM-CD6) interactions in different tissues [34-36]. With respect to ALCAM in murine 
tumor models, Hansen et al. reported ALCAM detection in histological sections of xenografted 
tumors derived from MDA-MB-231 breast cancer cells by immunofluorescence staining, 
although the effects of ALCAM targeting on tumorigenesis were not evaluated [37]. 
Remarkably, ALCAM knockdown induced a reduction in tumor cell growth as compared to 
controls in mouse models of endometrial and pancreatic cancer as well as hepatocellular 
carcinoma [38-42]. 
In a previous study [20], we have found that ALCAM-silenced breast cancer cells 
displayed reduced binding to immobilized Gal-8 relative to control cells. Importantly, our studies 
also highlighted that extracellular Gal-8 promoted receptor segregation, probably trapping 
ALCAM at the surface of breast cancer cells [20]. When analyzing ALCAM-Gal-8 interactions 
by surface plasmon resonance (SPR), we were able to prove that this lectin recognizes its ligand 
in a glycan-dependent manner [20]. In this regard, as observed with other “tandem-repeat“ type 
galectins [43-45], full-length Gal-8 presents a broader specificity for N-acetyllactosamine 
derivatives when compared to each of its CRDs separately: while Gal-8 N-CRD (Gal-8N) 
exhibits marked preference for α(2-3)-sialylated or 3-sulfated β-galactosides [43-47], Gal-8C 
shows preferential recognition for A- or B-blood group structures. As a consequence, full-length 
Gal-8 is able to elicit particular effects on the cell surface by synergistic action of both CRDs, 
involving interactions with high density ligands of moderate affinity for each isolated CRD [45]. 
Herein, we investigated the physiologic relevance of ALCAM-Gal-8 interactions in breast 
cancer cells. We found that ALCAM knockdown in MDA-MB-231 breast cancer cells decreases 
cell adhesion and migration onto Gal-8 surfaces in a glycan-dependent fashion. Moreover, 
silencing of Gal-8 or ALCAM prevented cell-cell adhesion, whereas dual silencing 
synergistically delayed in vivo tumor growth. Detailed structural N-glycoprofiling of ALCAM 
purified from MDA-MB-231 breast cancer cells revealed the presence of abundant permissive 
structures for Gal-8 binding. Furthermore, our results showed that cell sialylation modulates 















demonstrate a central role of either ALCAM or Gal-8 (or both) in controlling triple negative 
breast cancer. 
2. Materials and methods 
2.1. Reagents 
Polyvinylidene-difluoride (PVDF) membranes and Affi-Gel 10 were obtained from Bio Rad 
(Hercules, CA, USA). Anti-rabbit IgG conjugated to horseradish peroxidase (HRP), anti-β-actin, 
lactose, sucrose, aprotinin, sodium pyrophosphate, L-glutamine, 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT), saponin, paraformaldehyde, bovine serum albumin (BSA), 
and phenylmethylsulfonyl fluoride (PMSF) were obtained from Sigma-Aldrich (St. Louis, MO, 
USA). The monoclonal anti-Gal-8 antibody was purchased from Abcam (Cambridge, MA, USA). 
The anti-ALCAM monoclonal antibody (clone MOG/07, NCL-CD166) was obtained from 
Novocastra-Leica (Newcastle, UK); anti-ALCAM monoclonal antibody from Abcam (clone 3A6) 
was also used. Dulbecco’s modified Eagle’s medium, streptomycin/penicillin, 4',6-diamidino-2-
phenylindole (DAPI), Alexa Fluor 488-conjugated secondary antibody (Molecular Probes), 
matrigel Geltrex (growth factor-reduced) and recombinant human ALCAM were obtained from 
Invitrogen Life Technologies (Carlsbad, CA, USA). Fetal bovine serum (FBS) was purchased 
from Natocor (Villa Carlos Paz, Córdoba, Argentina). Diazabicyclo[2.2.2]octane (DABCO) was 
obtained from Fluka (Steinheim, Germany). Alexa Fluor 555-conjugated and HRP-conjugated 
anti-mouse IgG were purchased from Cell Signaling (Danvers, MA, USA). Pierce ECL Plus 
Western Blotting substrate was purchased from Thermo Fisher Scientific (Waltham, MA, USA). 
Maackia amurensis II (MAL II) and Sambucus nigra agglutinin (SNA) plant lectins were 
obtained from Vector Laboratories (Burlingame, CA, USA). 
2.2. Cell lines, constructs and generation of cell lines 
 
MDA-MB-231 (ATCC HTB-26) breast cancer cells were cultured in Dulbecco’s modified 
Eagle’s medium containing 25 mM glucose, supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 2 mM L-glutamine, 100 μg/ml streptomycin and 100 units/ml penicillin. Cells were 
detached from the plates with EDTA (0.53 mM EDTA, 140 mM NaCl, 5.4 mM KCl, 5.5 mM 
glucose, pH 7.2). To establish MDA-MB-231 cell lines in which Gal-8 expression was stably 
knocked-down, cells were transduced with specific shRNA lentiviral particles (sc-37429-V, Santa 
Cruz Biotechnology), following the manufacturer´s instructions. To establish MDA-MB-231 cell 















ALCAM-specific shRNA lentiviral particles (sc-43023-V, Santa Cruz Biotechnology). Control 
lentivirus (sc-108080, Santa Cruz Biotechnology), carrying scrambled-shRNA, was used for 
mock transduction. Finally, cells were selected in 1 μg/ml puromycin, Gal-8 and ALCAM 
expression were evaluated by Western blot, and knocked-down or mock-transduced cells were 
cultured and maintained in 1 μg/ml puromycin-containing culture medium. For analysis of Gal-8 
secretion, subconfluent cell monolayers were cultured with or without FBS for 24-48 h, and then 
conditioned media were collected and centrifuged for 10 min at 400 x g; sodium dodecyl sulfate 
(SDS) was added to the supernatants to a 0.5% (w/v) final concentration, then heated at 100 °C 
for 10 min, and diluted with 1:10 methanol, followed by a -20 °C overnight incubation; after 
centrifugation at 21,000 x g for 30 min, pellets were recovered and protein concentration was 
determined. 
2.3. Western blot analysis 
Cells were homogenized in lysis buffer (100 mM Tris, pH 7.4, 1% v/v Triton X-100, 10 mM 
EDTA, 100 mM sodium pyrophosphate, 4 mM PMSF). Cell lysates were centrifuged for 10 min 
at 12,000 x g at 4 ºC, supernatants were collected and protein concentration was determined. 
Samples from cell lysates or conditioned media (30 μg of protein/lane) were separated by SDS-
PAGE, and then electrotransferred onto PVDF membranes. Blots were probed with the primary 
antibodies overnight at 4 ºC. Detection of β-actin with anti-β-actin antibody was used to 
normalize protein loading in cell lysates. After incubating with the corresponding HRP-
conjugated secondary antibodies, immunoreactive bands were detected by chemiluminiscence. 
Densitometric analysis of protein levels was performed using Image J software (U.S. National 
Institutes of Health, Bethesda, MD, US; http://rbsweb.nih.gov/ij/). 
 
2.4. Cell adhesion assay 
Recombinant full-length Gal-8 (medium Gal-8 or M isoform; rGal-8) was prepared as previously 
reported [20,29]. Tissue culture plates (96-wells) were coated with rGal-8 (0.25-3 M) or BSA 
(0.1% w/v) overnight at 4 °C, and blocked with BSA (0.1% w/v) for 1 h at room temperature. 
Cells were detached from the plates with EDTA, washed with PBS, resuspended in FBS-free 
medium, and 2-3 x 10
4
 cells/well were seeded onto the coated plates incubating for 1-2 h at 37 ºC. 
Afterwards, cells were washed, fixed in 4% paraformaldehyde and stained with 0.5% crystal 
violet in acetic acid 3% (v/v) for 20 min at room temperature. Excess dye was removed by three 
washes with water, and cells were solubilized in 1% SDS (w/v) at room temperature for 1 h. Cell 















(Amersham Bioscience-GE Healthcare, Buckinghamshire, UK). Specific binding was defined as 
the difference between the absorbance of cells binding to rGal-8-coated wells and the absorbance 
of cells binding to BSA-coated wells. All assays were performed in triplicate. When indicated, 
coating was performed after incubating rGal-8 (2 M) with disaccharides such as lactose (100 
mM) or sucrose (100 mM) at room temperature for 30 min. 
 
2.5. Indirect immunofluorescence 
Cells were grown on uncoated coverslips in 24-well plates for 48 h. Cells were then rinsed twice 
in cold PBS and fixed in 4% paraformaldehyde at 0 ºC for 30 min. After washing, cells were 
blocked in 5% heat-inactivated human serum; when indicated, permeabilization was performed in 
0.05% saponin in PBS for 1 h. Staining for ALCAM was performed by incubating with an anti-
ALCAM monoclonal antibody overnight at 4 ºC, followed by Alexa Fluor 555-conjugated 
secondary antibody for 1 h at room temperature. Negative controls were performed by 
substituting the primary antibody by PBS, followed by the corresponding secondary antibody. 
Nuclei were stained with DAPI. Samples were mounted in DABCO and observed under a Fluo 
View FV1000 confocal microscope (Olympus, Tokyo, Japan). 
 
2.6. Scratch wound assay 
Migration was evaluated by means of the scratch wound assay. Thus, 1 x 10
4
 cells/well were 
seeded onto 96-well plates, containing different concentrations of full-length rGal-8 (2 M). Cells 
were allowed to grow to confluence in DMEM in the presence of 10% FBS for 48 h. Finally, a 
scratch was performed using a 20-µl tip, and cells were washed twice with PBS and incubated 
with DMEM without FBS for 20 h at 37 ºC. Cells were photographed and Image J software was 
used to determine the whole area of the wound at 20 h versus 0 h (wound closure (%) = [area at 
20 h / area at 0 h x 100]). When indicated, pre-coating was performed after incubating the lectin 
with disaccharides such as lactose (100 mM) or sucrose (100 mM) at room temperature for 30 
min. 
 
2.7. Cell aggregation assay 
To analyze cell-cell interactions, single-cell suspensions were prepared, and 5 x 10
3
 cells/sample 
were incubated in FBS-free DMEM with gentle rotation (80 rpm) at 37 °C for 1 h, in microfuge 
tubes. Then, each sample was loaded onto different wells of 96-well plates to be photographed. 
The number of free cells was counted at 0 and 1 h in five fields/sample. The percentages of free 















of free cells at 0 h x 100]), and each assay was performed in triplicates. When indicated, 
aggregation was performed adding soluble rGal-8 (1-5 µM). To determine if the aggregation 
process was carbohydrate-dependent, cells were incubated with rGal-8 (2 µM) and disaccharides 
(lactose as a competitor for Gal-8 binding, and sucrose as a negative control, 100 mM). 
 
2.8. Cell proliferation 
Measurements of cell viability were determined using the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay. Briefly, 0.3 x 10
4
 cells/well were plated in 96-well 
plates in DMEM plus 10% FBS, and allowed to attach for 24 h at 37 ºC. Then, cells were 
incubated in FBS-free DMEM for 24 h at 37 ºC. Afterwards, cells were incubated in DMEM 
containing 10% FBS, and cell proliferation was measured after 0, 24, 48, 72 and 96 h. Briefly, at 
any indicated time, 20 l of MTT solution (4 mg/ml) was added to each well, and the plates were 
incubated for an additional 2 h at 37 ºC. In order to solubilize the formazan crystals formed in 
viable cells, dimethyl sulfoxide (150 l) was added to each well, before measuring the absorbance 
at 595 nm. 
 
2.9. Colony formation 
To evaluate the ability of single cells to form colonies, 0.3 x 10
3
 cells/well were loaded in 24-well 
plates in DMEM with 10% FBS. Cells were incubated for 10 days at 37 °C, and culture medium 
was replaced every 3 days. Afterwards, cells were washed, fixed in 4% paraformaldehyde and 
stained with 0.5% crystal violet in acetic acid 3% (v/v) for 20 min at room temperature. Colonies 
were photographed and quantified under a light microscope. 
 
2.10. Spheroid-formation assay 
Fifty microliters of matrigel Geltrex/well were loaded into 96-well plates, which were incubated 
for 2 h at 37 °C. Cells were seeded onto matrigel at a density of 1 x 10
4
 cells/well in DMEM plus 
10% FBS. Culture medium was replaced every 3 days. After 10 days at 37 °C, spheroids were 
photographed under a light microscope. Each assay was performed in triplicates. Spheroids were 
photographed in five fields/sample, and their volumes were measured using Image J software, 
applying the formula: [volume (mm
3
) = 4/3 π r
3
], where r is the sphere radius. 
 
















Animal care and manipulation were performed in agreement with the National Institutes of 
Health guide for the care and use of laboratory animals (NIH Publications Number 8023, revised 
1978). The Ethical Committee from Instituto de Oncología Angel H. Roffo approved the 
experiments and the use of animals for this work, according to the institutional guidelines for 
animal welfare. Eight-week-old female athymic nude mice (Comisión Nacional de Energía 
Atómica, Ezeiza, Buenos Aires, Argentina) were subcutaneously inoculated with tumor cells. 
Each mouse was injected with 10
7
 cells/50 l of PBS plus 50 l of matrigel Geltrex, and each 
group of animals was composed of 5-6 mice. When tumors were palpable, sizes were measured 
with a Vernier caliper 2-3 times a week. Tumor volume was calculated with each radius (r1, r2 and 
r3), applying the formula: [volume (mm
3
) = 4/3 π r1 r2 r3]. Growth curves were performed plotting 
tumor volume versus time. Mice were sacrificed at 56 or 98 days after injection. Tumor growth 
and dissemination were evaluated macroscopically ex vivo. For histological analysis, all extracted 
tissues (tumors and lymph nodes) were fixed in 10% neutral buffered formalin, stained with 
haematoxylin and eosin, and evaluated by a pathologist. 
2.12. N-Glycoprofiling of endogenous ALCAM from MDA-MB-231 cells 
ALCAM from MDA-MB-231 cells was purified by affinity chromatography in a rGal-8-Affi-Gel 
10 column as previously described [20,29]. After blotting onto PVDF membranes, this 
glycoprotein was identified by Western blot, and de-N-glycosylated using peptide N-glycosidase 
F (1,000 U/ml; Roche, Manheim, Germany) for 16 h in 20 mM NaHCO3 buffer (37 ºC) [48]. 
Then, the digested N-glycans were separated by filtration (Nanosep 10K Omega, Pall Life 
Sciences, New York, NY, USA) and subsequently labelled with 2-aminobenzamide (2AB) by 
reductive amination. Excess of 2AB was removed by paper chromatography [49], or by 
LudgerClean S Cartridges (Ludger Ltd., Oxford, UK). Then, 2AB-labelled N-glycans were 
separated by ultra-performance hydrophilic interaction liquid chromatography (HILIC) with 
fluorescence detection (FLR λex = 330 nm, λem = 420 nm) using a BEH Glycan column (150 x 2.1 
mm, 1.7 μm bridged ethylsiloxane/silica hybrid particles, Waters, Milford, MA, USA) on an 
Acquity H-Class instrument (Waters, Milford, MA, USA). Solvent A was 50 mM formic acid 
adjusted to pH 4.4 with ammonia solution. Solvent B was acetonitrile. The column temperature 
was set to 40 °C. The 30 min method was used with a linear gradient of 30−47% with buffer A at 
0.56 mL/min flow rate for 23 min followed by 47−70% A and finally reverting back to 30% A to 
complete the run method [50]. The injection volume was 10 µl, and samples were prepared in 
70% (v/v) acetonitrile and stored at 5 ºC before injection. A dextran hydrolysate ladder was used 















Waters Empower 3 chromatography workstation software. Structural analysis of the released N-
glycans was assisted by digestion with exoglycosidases [51], including: α(1-3,4)-fucosidase 
(cloned from sweet almond tree and expressed in Pichia pastoris); α(2-3,6,8,9) neuraminidase A 
(cloned from Arthrobacter ureafaciens and expressed in E. coli); α(2-3) neuraminidase  and β(1-
4)-galactosidase (both cloned from Streptococcus pneumoniae and expressed in E. coli); α(1-2,3)-
mannosidase (cloned from Xanthomonas manihotis and expressed in E. coli). Enzymatic 
digestions were performed on 2AB-labelled N-glycans in manufacturer’s recommended buffers 
for 16 h at 37 ºC. After digestion, N-glycans were separated from exoglycosidases before 
chromatographic analysis by centrifugation in a Nanosep 10K Omega microcentrifuge filter (Pall 
Life Sciences, New York, USA). All exoglycosidases were purchased from New England Biolabs 
(Massachussets, USA). 
For sialylation analysis, separation of neutral and acidic oligosaccharides was 
performed by Weak Anion Exchange (WAX) chromatography (WAX-HPLC) using a BioSuite 
DEAE 2.5 m NP AXC 4.6 x 35 mm column (Waters, Milford, MA, USA). Solvent A was 
ammonium acetate 50 mM (pH 7.0) in 20% v/v acetonitrile, and solvent B was 20% v/v aqueous 
acetonitrile. Gradient conditions were as follows: an initial equilibration of 2 min of 0% A, a 
linear gradient of 0 to 40% A over 4 min at a flow rate of 0.5 ml/min, followed by 40 to 100% A 
over 3 min, then 4 min at 100% A, 100 to 0% A over 0.5 min, and then 3.5 min at 0% A. Samples 
(10 µL) were injected in water and fluorescently-labelled fetuin N-glycans were used as a 
reference [50]. As both sialylation and sulfation can provide negative charge to 2AB-labelled N-
glycans, digestion with α(2-3,6,8,9) neuraminidase A was performed to confirm absence of 
sulfated structures. Percentage of α(2-3) sialic acid was determined by specific cleavage with α(2-
3) neuraminidase. 
 
2.13. Characterization of cell surface sialylation by flow cytometry 
MDA-MB-231 cells (1 x 10
6
) were washed three times in PBS, and incubated in 250 l of 
DMEM FBS-free containing either 20 U α(2-3,6,8,9) neuraminidase A or 40 U α(2-3) 
neuraminidase at 37 ºC for 2 h. After washing, cell sialylation was evaluated by flow cytometry 
using biotin-conjugated plant lectins including Maackia amurensis II (MAL II), which recognizes 
α(2-3)- sialylated structures (10 µg/ml), and Sambucus nigra agglutinin (SNA), which recognizes 
α(2-6)-sialylated glycans (5 µg/ml). In brief, unspecific interactions with plant lectins were 
avoided by washing in 1% BSA-PBS, and incubating cells with biotin-conjugated MAL II and 
SNA in 1% BSA, 10 mM HEPES, 150 mM NaCl, pH 7.4 on ice for 1 h. After washing, cells 















Cells were then washed, fixed in 4% paraformaldehyde, and analyzed by flow cytometry in a 
PASS III flow cytometer (Partec, Görlitz, Germany). Twenty thousand events were acquired for 
each sample, and data analysis was performed using FlowJo LLC (Ashland, Oregon, USA) 
software program. 
 
2.14. Statistical analysis 
Data were analyzed using GraphPad Prism 6.01 Software (GraphPad Software Inc., La Jolla, CA, 
US) and results are expressed as the mean ± standard error of the mean (S.E.M.) from, at least, 
three independent experiments. Differences between groups were assessed by one-way analysis 
of the variance (ANOVA) or two-way ANOVA (with appropriate post-tests). Values of p<0.05 
were considered statistically significant. 
 
3. Results 
3.1 Silencing ALCAM in MDA-MB-231 breast cancer cells decreases cell adhesion and 
migration onto Gal-8-coated plates 
 
To understand the role of Gal-8 and ALCAM in breast cancer cell interactions and motility, we 
silenced both Gal-8 and ALCAM in MDA-MB-231 cells. Cells were transduced with ALCAM-
specific shRNA lentiviral particles (MDA-shALCAM) or Gal-8-specific shRNA lentiviral 
particles (MDA-shGal8), while control cells were transduced with scrambled-shRNA lentiviral 
particles (mock-transduced; MDA-shControl). Gal-8 knockdown (Fig. 1A) in MDA-shGal8 cells 
rendered approximately 50% reduction in protein expression, while ALCAM knockdown (Fig. 
1B) in MDA-shALCAM showed 80% decrease in protein level, as determined in both cases 
against MDA-shControl by Western blot. Finally, a Gal-8- and ALCAM-double-silenced cell line 
(MDA-shALCAM-shGal8) was generated, obtaining 50% and 80% of Gal-8 (Fig. 1A) and 
ALCAM (Fig. 1B) silencing, respectively. 
To analyze interactions between MDA-MB-231 cell surface ALCAM and Gal-8, we 
evaluated cell adhesion using full-length rGal-8-coated plates. We observed enhanced cell 
adhesion with increasing rGal-8 concentrations (0.25-3 M) for all cell lines analyzed (Fig. 1C). 
MDA-shALCAM and MDA-shALCAM-shGal8 cells, which exhibited low levels of surface 
ALCAM (Fig. 1D), showed significantly reduced adhesion to rGal-8-coated plates (p0.05) 
compared to MDA-MB-231, MDA-shControl or MDA-shGal8 cells (Fig. 1C), highlighting the 
relevance of interactions between endogenous ALCAM and extracellular Gal-8 in tumor cell 















shALCAM-shGal8 cell adhesion on rGal-8-coated plates (1-3 M). Similarly, no significant 
differences in cell adhesion on rGal-8-coated plates were observed between MDA-MB-231, 
MDA-shControl or MDA-shGal8 cells (Fig. 1C). Remarkably, cell adhesion on rGal-8-coated 
plates (2 M) was shown to be carbohydrate-dependent as 100 mM lactose, a galectin-specific 
ligand, was able to inhibit adhesion in the three ALCAM
+
 (MDA-MB-231, p0.05; MDA-
shControl, p0.05; MDA-shGal8, p0.05) cell lines, whereas sucrose (100 mM) -a non-specific 
disaccharide- did not show any effect (Fig. 1E). Interestingly, in ALCAM-silenced cell lines 
(MDA-shALCAM and MDA-shALCAM-shGal8 cells), adhesion on rGal-8-coated plates was not 
significantly reduced by lactose. In conclusion, ALCAM silencing in MDA-MB-231 cells 
decreases in vitro cell binding to rGal-8, and the ALCAM-Gal-8 interactions are -at least 
partially- glycan-mediated. Although other cell surface Gal-8 ligands could also be involved in 
cell adhesion, such as integrins [5,6,22], these results suggest a main role for glycan-dependent 
ALCAM-Gal-8 interactions operating at the surface of MDA-MB-231 cells. 
In 2D wound healing assays, ALCAM silencing decreased the wound closure rate of 
MDA-MB-231 cells onto rGal-8-coated (2 M) surfaces (Fig. 2). ALCAM
+
 cell lines (MDA-
MB-231, MDA-shControl and MDA-shGal8 cells) migrated significantly faster (p0.001) onto 
rGal-8 than ALCAM-silenced (MDA-shALCAM and MDA-shALCAM-shGal8) cells after 20 h 
(Fig. 2A, B). Moreover, MDA-MB-231, MDA-shControl or MDA-shGal8 cells (ALCAM
+ 
cells) 
showed significantly enhanced cell migration onto rGal-8-coated plates when compared to 
uncoated wells (p0.001, p0.01 and p0.01, respectively; Fig. 2A, B). Conversely, ALCAM-
silenced cell lines showed a trend towards an increased migration onto rGal-8-coated plates 
versus uncoated surfaces, which did not reach statistical significance (Fig. 2A, B). Hence, the 
stimulatory effect of rGal-8 on cell migration was only significant in ALCAM
+
 cell lines, thus 
indicating a role for surface ALCAM-extracellular Gal-8 interactions on breast cancer cell 
migration. In the case of uncoated culture plates, while Gal-8 silencing did not modify the rate of 
migration in MDA-MB-231 cells, ALCAM silencing did significantly reduce (p0.001) cell 
motility (Fig. 2A, B). Importantly, cell migration onto rGal-8-coated surfaces was markedly 
inhibited by lactose (10.12±1.78%) in the three ALCAM
+
 (MDA-MB-231, p0.001; MDA-
shControl, p0.01; MDA-shGal8, p0.01) cell lines (Fig. 2C, D), but not by the unrelated 
disaccharide sucrose (Fig. 2C, D). In contrast, in ALCAM-silenced (MDA-shALCAM and MDA-
shALCAM-shGal8) cells, migration onto rGal-8-coated wells was not significantly reduced by 
lactose (4.95±0.35%), suggesting a main role for glycan-dependent ALCAM-Gal-8 interactions in 















MDA-MB-231 cells decreases in vitro cell migration both onto rGal-8-coated surfaces and onto 
uncoated culture plates. Importantly, a favourable glycan-mediated effect of rGal-8, acting as a 
matricellular ligand, is observed on the motility of ALCAM
+
 cells, which is abrogated by 
ALCAM knockdown, highlighting the relevance of glycan-dependent ALCAM-Gal-8 
interactions at the surface of MDA-MB-231 cells. 
 
3.2 Silencing of Gal-8 and ALCAM in MDA-MB-231 breast cancer cells decreases cell-cell 
adhesion in a 3D model 
 
To mimic in vitro tumor progression, we used a 3D model to study the formation of cell 
aggregates. Thus, we developed a cell aggregation assay and quantitatively determined Gal-8 and 
ALCAM effects in cell-cell adhesion. Gal-8 silencing markedly inhibited cell aggregation in 
MDA-MB-231 cells: notably, MDA-shGal8 cells exhibited significantly increased percentage of 
free cells (p0.05) when compared to MDA-shControl cells after 1 h of cell-cell adhesion (Fig. 
3A, B). Similarly, ALCAM-silenced tumor cells showed significantly reduced (p0.05) cell-cell 
adhesion as compared to MDA-shControl cells (Fig. 3A, B). 
Exogenously-added soluble rGal-8 (1 M) rendered a significant increase in cell aggregation 
in Gal-8-silenced cells (MDA-shGal8 cells, p0.001; MDA-shALCAM-shGal8 cells, p0.05) 
(data not shown), demonstrating the role of secreted Gal-8 in cell-cell interactions in the 
extracellular milieu. In control MDA-MB-231 and MDA-shControl cells, increasing 
concentrations of exogenous soluble rGal-8 (2-5 M) significantly increased aggregation in a 
glycan-dependent manner (Fig. S1). 
In conclusion, either Gal-8 or ALCAM silencing attenuates cell-cell aggregation, although 
dual silencing does not produce any enhanced effect. 
 
3.3 ALCAM silencing inhibits cell proliferation in MDA-MB-231 breast cancer cells 
 
Next, we examined whether ALCAM or Gal-8 may also affect cell proliferation of MDA-MB-
231 cells (Fig. 4A). After 72 hour incubation, MDA-shALCAM-shGal8 cells showed decreased 
proliferation compared to MDA-MB-231 (p0.05), MDA-shControl (p0.01) and MDA-shGal8 
(p0.05) cells, as measured by colorimetric MTT-based assay. Interestingly, at 96 h, both MDA-
shALCAM (p0.05; p0.01) and MDA-shALCAM-shGal8 (p0.001; p0.001) cells showed 
decreased proliferation compared to control MDA-MB-231 and MDA-shControl cells, 
respectively. MDA-shALCAM (p0.01) and MDA-shALCAM-shGal8 (p0.001) cells also 

















 cell lines or between ALCAM-silenced cell lines at 72 or 96 h 
(Fig. 4A), indicating that ALCAM silencing -but not Gal-8 silencing- decreased MDA-MB-231 
cell proliferation. Furthermore, we found that ALCAM-silenced cells showed impaired ability to 
form anchorage-dependent colonies (p0.001) compared to ALCAM
+
 cells (MDA-MB-231, 
MDA-shControl and MDA-shGal8 cells) (Fig. 4B). Accordingly, when we evaluated spheroid 
formation after 10 days, ALCAM-silenced cells produced spheres with significantly reduced 
volumes (p0.001) compared to those derived from ALCAM
+
 cells (Fig. 4C). We conclude that 
ALCAM silencing reduces MDA-MB-231 cell ability to form colonies and spheroids, which is 
probably related to the effects of ALCAM silencing on cell proliferation. Thus, ALCAM is 
involved in cell growth and survival of human MDA-MB-231 breast cancer cells. 
 
3.5 Silencing ALCAM and Gal-8 affects primary tumor growth in a murine model of triple 
negative breast cancer 
 
To analyze the effect of Gal-8 and ALCAM on tumor development and metastasis, we 
subcutaneously inoculated human MDA-MB-231 breast tumor cells in athymic nude mice. At 
day 56 post-inoculum (p.i.), MDA-shGal8 cells generated smaller tumors (p0.05) than control 
MDA-MB-231 and MDA-shControl cells (Fig. 5A, B). Tumors developed from control MDA-
shControl cells did not show any significant difference in volume as compared to those derived 
from MDA-MB-231 control cells at any time evaluated (Fig. 5 A, B). Control mice as well as 
mice inoculated with MDA-shGal8 cells were euthanized because of ethical reasons at day 56 p.i. 
to allow the comparisons between groups. ALCAM-silenced cells developed very small tumors 
after 56 days of injection (p0.01) as compared to tumors derived from control MDA-MB-231 
and MDA-shControl cells (Fig. 5 A, B). Moreover, at day 56 p.i., mice inoculated with MDA-
shALCAM and MDA-shALCAM-shGal8 cells developed significantly smaller tumors (p0.05) 
than those inoculated with MDA-shGal8 cells (Fig. 5 A, B). Mice injected with MDA-shALCAM 
and MDA-shALCAM-shGal8 cells were kept alive to monitor potential growth differences 
between experimental groups. Notably, at day 98 p.i., we observed that tumors generated by 
MDA-shALCAM-shGal8 cells were smaller (p0.05) than those generated by MDA-shALCAM 
cells (Fig. 5A). In summary, dual silencing of Gal-8 and ALCAM induced a significant delay on 
tumor growth, even more pronounced as that observed following Gal-8 or ALCAM silencing 
alone. In order to evaluate if Gal-8 and ALCAM were still efficiently downregulated in primary 
tumors developed in different groups, Western blot analysis was performed after tumor resection. 
Tumors derived from MDA-shGal8 cells showed significantly decreased Gal-8 protein levels at 















observed in tumors generated by MDA-shALCAM-shGal8 cells (p0.05) at day 98 p.i. (Fig. 5C, 
left panel). Tumors generated by ALCAM-silenced cells showed significantly lower ALCAM 
expression (p0.001) at day 98 p.i. than those generated by control or MDA-shGal8 cells at day 
56 p.i. (Fig. 5C, right panel). 
Regarding local metastasis, a tendency to reduction in the number of mice bearing 
metastasis in tumor-draining lymph nodes (Fig. 5D) was observed after Gal-8 and ALCAM 
silencing, which was not statistically significant. However, tumors generated by MDA-shGal8 
cells developed only micrometastases (2/6 mice) surrounded by hyaline stroma unlike the 
massive metastases observed in 62.5% of the mice inoculated with control cells (Fig 5D). 
Remarkably, lung metastases were not observed. Thus, silencing of both Gal-8 and ALCAM 
synergistically slows down tumor growth in a murine model of triple negative breast cancer. 
 
3.6 Cell surface sialylation influences MDA-MB-231 cell adhesion onto Gal-8-coated surfaces 
We have previously described a predominant (2-6) sialylation in ALCAM derived from MDA-
MB-231 cells [20]. In this work, we expanded this analysis and structurally characterized the 
complete N-glycan profile of ALCAM by HILIC-FLR and exoglycosidase digestions (Fig. 6, 
Table S1). We identified 34 structures including a major proportion of complex N-glycans, with 
prevalent bi- or tri-antennary structures. No α(1-3,4)-antenna fucosylation was detected by 
specific exoglycosidase digestion, and core α(1-6)-fucosylated structures represented only 30% of 
the complex N-glycan structures characterized. Moreover, ALCAM complex N-glycans presented 
no sulfation and around 30% of sialylated structures [20]. Considering that α(2-3)-sialylated N-
glycans are recognized by Gal-8 while α(2-6)-sialylated structures are not, we further analyzed 
sialic acid linkage type by using a specific α(2-3) neuraminidase and an α(2-3,6,8,9) 
neuraminidase A. Our results showed that monosialylated glycans are α(2-3)-sialylated, while the 
proportions of α(2-3) and α(2-6)-sialylated structures varied in di- and tri-sialylated structures. 
Tetrasiaylated structures were represented by approximately 2.5% of the complete profile, and, 
due to their low abundance, they could not be fully characterized. Interestingly, structures 
permissive for Gal-8 binding were detected in 45% of either (2-3)-sialylated or neutral terminal 
N-acetyllactosamine residues (Fig. 6E). Another 18% of sialylated N-glycans could be recognized 
by this “tandem-repeat” type galectin following α(2-3,6,8,9) neuraminidase A treatment (a total 
of 63% of all N-glycans) (Fig. 6F). Finally, high mannose-type N-glycans (M5-M9) represented 
30% of the complete profile, with Man7 being the most abundant glycan (Fig. 6, Table S1). In 















permissive for Gal-8 binding, and digestion with α(2-3,6,8,9) neuraminidase A considerably 
increases the number of structures recognized by this lectin. 
Seeking for a correlation at the cellular level, MDA-MB-231 cells were desialylated 
with α(2-3,6,8,9) neuraminidase A or a specific α(2-3) neuraminidase. Sialylation before and after 
each treatment was assessed by flow cytometry using biotin-conjugated Maackia amurensis II 
(MAL II, a lectin capable of recognizing α(2-3) sialic acid moieties) and Sambucus nigra (SNA, a 
lectin with affinity for α(2-6)-linked sialic acid) (Fig.7A). As expected, both neuraminidases 
completely abrogated MAL II binding, while treatment with neuraminidase A significantly 
reduced SNA binding (Fig.7A). Next, cell adhesion assays were performed in 96-well tissue 
culture plates coated with full-length rGal-8 (5 M; a higher lectin concentration was used in this 
assay to improve sensitivity of the method) or BSA as a negative control. We evaluated MDA-
MB-231, MDA-shControl, MDA-shGal8, MDA-shALCAM, and MDA-shALCAM-shGal8 cells 
treated with α(2-3,6,8,9) neuraminidase A or α(2-3) neuraminidase. Notably, for each ALCAM
+
 
cell line (MDA-MB-231, MDA-shControl and MDA-shGal8), both neuraminidases significantly 
increased adhesion onto rGal-8-coated surfaces versus untreated cells or versus ALCAM-silenced 
cell lines (Fig. 7B). On the contrary, ALCAM-silenced cell lines only showed a tendency to 
increase cell adhesion after desialylation when compared to untreated cells (Fig. 7B). Thus, 
treatment with neuraminidases unmasks Gal-8 ligands -as reported by others [45]- and modulates 
Gal-8 activity, especially in ALCAM
+ 
cells. Altogether, these results showed that the combined 
effects of desialylated Gal-8 ligands, including ALCAM, increased MDA-MB-231 cell adhesion 
onto Gal-8-coated surfaces. 
 
4. Discussion 
Galectins have been proposed to serve as matricellular proteins that modulate a myriad of 
extracellular and intracellular events [4,6,52]. In particular, Gal-8 has been shown to act as a 
matrix protein capable of promoting cell adhesion by ligating and inducing clustering of several 
surface receptors, i.e. integrins, in different cell types [6,23-27]. This study reports, for the first 
time, that extracellular Gal-8 acts as a matrix protein promoting cell adhesion and migration via 
glycan-dependent ALCAM-Gal-8 interactions. ALCAM silencing in MDA-MB-231 cells 
decreased cell adhesion onto rGal-8-coated surfaces in a glycan-dependent manner, while in 
wound healing assays, ALCAM silencing decreased MDA-MB-231 cell migration both onto 
rGal-8-coated and uncoated culture plates. Importantly, we have shown that interaction of 
extracellular rGal-8 with ALCAM
+
 cells is crucial for MDA-MB-231 cell motility, and it is 















after 20 h-treatment, which might be attributed to two events: 1) Gal-8 protein was not 
completely silenced in Gal-8-knocked-down cells (only 50%); 2) after 20 h-treatment, secreted 
Gal-8 levels were probably too low and similar between MDA-shGal8 and control cells. 
Therefore, we propose that extracellular Gal-8 mediates cell migration, and both cell lines secrete 
insufficient Gal-8 to coat plastic surfaces after 20 h-treatment. In fact, similar results were 
obtained by other authors as Gal-8 silencing did not affect migration after 16 h [26], whereas 
extracellular Gal-8 readily promoted cell motility [6,25,26]. On the other hand, the role of 
ALCAM in MDA-MB-231 cell migration is still under discussion: ALCAM silencing in these 
cells has been shown to increase cell migration on plastic and to reduce cell invasion [53], or to 
have no evident effect [37]. Depending on tumor type, ALCAM silencing reduced cell migration, 
invasion and adhesion [42], increased cell migration and invasion [38], or displayed a non-
significant increase in spontaneous migration [37]. 
Regarding intercellular adhesion, either Gal-8 or ALCAM silencing diminished 
homotypic aggregation of MDA-MB-231 cells. Accordingly, silencing of Gal-8 has been shown 
to reduce homotypic aggregation in prostate cancer cells [54]. Moreover, and as previously 
shown [45], we found that exogenously-added soluble rGal-8 (1 M) increased intercellular 
adhesion of Gal-8-silenced cells (data not shown). As expected, increasing concentrations of 
soluble rGal-8 significantly promoted enhanced cell aggregation of ALCAM
+
 control cells, which 
still occurred even at high doses (5 M, Fig. S1), highlighting the role of extracellular Gal-8 in 
cell-cell interactions. 
Importantly, our results also showed that ALCAM is involved on cell growth, because 
MDA-shALCAM and MDA-shALCAM-shGal8 cells exhibited decreased cell proliferation. 
Likewise, ALCAM silencing reduced MDA-MB-231 cell ability to form colonies and spheroids, 
an effect which was likely associated to the adverse effect of ALCAM silencing on cell 
proliferation. Similar ALCAM effects on cell growth or colony formation have been reported by 
other authors in different tumor cell types [37-41,55]. Our results showed that Gal-8 silencing in 
MDA-MB-231 cells did not affect proliferation and colony formation, as reported for other 
cancer cell types [54]. 
Interestingly, in addition to in vitro effects, we also report the effects of silencing either 
ALCAM or Gal-8 on tumor growth in a murine model of triple negative breast cancer. Our 
studies indicate that dual Gal-8 and ALCAM silencing synergistically slowed down tumor 
growth. In agreement with our results, in xenograft murine models, Gal-8 silencing totally 
abolished the metastatic ability of human IGR-CaP1 prostate cancer cells when studying 















the tumorigenicity of this cell line [54]. Gal-8 overexpression transformed MDCK cells, which 
formed larger tumors than parental cells in immunosuppressed mice [21]. With respect to 
ALCAM in murine tumor models, control endometrial cancer cells inoculated into uteri 
developed larger tumors compared to ALCAM-silenced cells. Moreover, mice injected with 
ALCAM-silenced cells developed fewer local metastases than control mice [42]. Likewise, in 
xenograft mouse models of hepatocellular carcinoma, ALCAM knockdown induced a reduction 
in tumor cell growth compared to control xenografts [39,41], while ectopic expression of 
ALCAM demonstrated its pro-carcinogenic properties [40]. Similarly, ALCAM
+
 pancreatic 
cancer cells were strongly tumorigenic as compared to ALCAM-silenced
 
cells, in both 
subcutaneous and orthotopic mouse tumor models [38]. In metastatic models, intracardiac 
injection of prostate cancer cells in nude mice resulted in decreased bone metastasis in ALCAM-
knocked down versus control cells [37]. 
In this study, we report the effect of MDA-MB-231 cell surface sialylation on cell adhesion 
onto rGal-8-coated surfaces. Noteworthy, in desialylated MDA-MB-231 cells, we observed 
increased adhesion to rGal-8-coated surfaces, both after removal of α(2-3,6,8,9) sialic acid 
residues, and after treatment with a specific (2-3) sialidase (Fig. 7B). These results show that 
full length Gal-8 interactions with MDA-MB-231 cells do not completely reflect affinity data 
obtained with separate CRDs, as previously described for other cell types: Carlsson et al. [45] 
showed that the average binding of full-length Gal-8 to U937 monocyte cells did not significantly 
change after treating cells with neuraminidase A or a specific α(2-3) neuraminidase. Moreover, it 
has been demonstrated that treatment of predominantly (2-3)-sialylated CHO cells with 
neuraminidase A increased full-length Gal-8 binding [56] and, accordingly, full-length Gal-8 
binding levels to wild-type and mutant CHO cells lacking sialic acid were not significantly 
different [57]. Consequently, cell surface full-length Gal-8 binding to MDA-MB-231 cells also 
results from the combined action of both domains [45]. As affinity and avidity of lectins for 
glycan epitopes depend on glycan density [58], evolution has provided ways for overcoming 
natural heterogeneity of cell surface glycosylation and still triggering key biological events. In 
certain genetically-modified mice lacking specific glycosyltransferases, overall expression of 
glycan ligands is regulated so lectins can still bind and there are no cellular dysfunctions [59]. To 
summarize, in the process of Gal-8-cell binding, we propose that a higher density of N-
acetyllactosamine (LacNAc) residues unmasked by enzymatic desialylation could compensate for 















ALCAM N-glycosylation profiling confirmed a high percentage of permissive structures 
for Gal-8 recognition and binding. Evaluation of the 34 characterized structures indicated that an 
important proportion of glycans (45%) could be recognized by Gal-8 through interactions with 
either (2-3)-sialylated or neutral terminal N-acetyllactosamine residues (Fig. 6E). When digested 
with an (2-3,6,8,9) neuraminidase, the percentage of permissive structures considerably 
increased (63%) (Fig. 6F). However, as exposure of glycan epitopes is dependent on 
glycoconjugate structure and abundance on the cell surface, not all permissive N-glycans 
described for ALCAM may be exposed or recognized by Gal-8 on these cells. 
To conclude, under our experimental conditions, cell desialylation increased MDA-MB-
231 cell adhesion onto Gal-8-coated surfaces (Fig. 7B). The impact of cell surface desialylation 
cannot be only attributed to ALCAM since integrins, among others, are also Gal-8 ligands 
[5,6,22] present in MDA-MB-231 cells [60-62]. In this sense, Yuan et al. reported that 
desialylation of α(2-6)-sialylated integrins increased adhesive affinity between MDA-MB-231 
cells and extracellular matrix proteins [60]. Accordingly, we propose that the desialylation of 
different Gal-8 ligands (i.e. ALCAM, integrins, CD44) synergistically promotes cell adhesion. 
Finally, our results demonstrate that glycan-dependent heterophilic interactions between 
ALCAM and Gal-8 operate at the cell surface of MDA-MB-231 triple negative breast cancer 
cells, which contribute to modulate cell adhesion and migration. In addition, both ALCAM and 
Gal-8 promote tumorigenesis in a synergistic way in MDA-MB-231 cancer cells, thus 
cooperating in tumor progression. Overall, we propose a model in which ALCAM and Gal-8 
represent not only binding partners (receptor and ligand) at the cell surface but also crucial 
interplaying molecules inside breast cancer cells. In fact, triple negative breast cancer represents 
15-20% of all breast cancers and is characterized by a very aggressive behavior with a peak risk 
of recurrence within three years of diagnosis, a scenario in which effective treatments for patients 
are mandatory [63]. Thus, an improved understanding of the mechanisms that govern the 
ALCAM/Gal-8 axis may contribute to design novel therapeutic strategies, in combination with 
chemotherapeutic and immunotherapeutic modalities, for triple negative breast cancer patients. 
 
5. Conclusions 
In this study, we demonstrate that Gal-8 acts as a matrix protein, which promotes cell 
adhesion and migration through glycan-dependent interactions with ALCAM at the surface of 
MDA-MB-231 breast cancer cells. Importantly, we found that cell sialylation modulates Gal-8-















aggregation, thus emphasizing the influence of both molecules in tumorigenesis. In addition, 
ALCAM silencing reduced MDA-MB-231 cell ability to proliferate, influencing colony and 
spheroid formation. Interestingly, in a triple negative breast cancer model, ALCAM and Gal-8 
acted synergistically to promote tumorigenesis. Of note, this is the first evidence demonstrating 
the effect of dual ALCAM and Gal-8 silencing on tumor growth in triple negative breast cancer. 
Further elucidation of the mechanisms through which the ALCAM/Gal-8 axis fuels tumorigenesis 
may contribute to design new drugs for triple negative breast cancer therapy. 
 
Acknowledgements 
F.F. is a fellow from Consejo Nacional de Investigaciones Científicas y Técnicas 
(CONICET). M.T.E, K.V.M., G.A.R, A.J.C., L.L.C and M.F.T. are researchers from CONICET. 
 
Funding 
This work was supported by Agencia Nacional de Promoción Científica y Tecnológica 
[PICT-2007-1631 and PICT-2012-0071 to MTE; PICT-2015-0564 to KVM], and CONICET 
[PIP-2015-1122015-0100647 to MFT]. GAR, KVM and AJC acknowledge support from 
Fundación Sales, Fundación René Barón and Fundación Bunge & Born. 
 
Authors’ contributions 
MTE, LLC, GAR and KVM: conceived and designed experiments; analyzed and interpreted 
data; wrote and revised the manuscript. FF, AJC, LLC and CST: executed experiments, analyzed 
data, and revised the manuscript. SIV: performed histopathological studies, analyzed and 
interpreted data. MFT and CWT: analyzed and interpreted data, and revised the manuscript. 
 
Disclosure of Potential Conflicts of Interest 
The authors declare no competing financial interests. 
Abbreviations 
A, absorbance; 2AB, 2-aminobenzamide; ALCAM, activated leukocyte cell adhesion molecule; 
Bcl-2, B-cell lymphoma 2 protein; BSA, bovine serum albumin; CRD, carbohydrate recognition 
domain; DABCO, diazabicyclo[2.2.2]octane; DAPI, 4',6-diamidino-2-phenylindole; DMEM, 
Dulbecco's Modified Eagle Medium; EDTA, ethylene-diaminetetraacetic acid; FBS, fetal 
bovine serum; FLR, Fluorescence detector; Gal-8, galectin-8; HILIC, Hydrophilic interaction 















MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; PBS, phosphate-buffered 
saline; PE, phycoerythrin; PMSF, phenylmethylsulfonyl fluoride; PVDF, polyvinylidene-
difluoride; rGal-8, recombinant galectin-8; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis; shRNA, short hairpin RNA; shGal-8, shRNA specific for galectin-8; 
shALCAM, shRNA specific for ALCAM; SNA, Sambucus nigra agglutinin; SPR, surface 
plasmon resonance; WAX, Weak Anion Exchange chromatography. 
 
References 
[1] J.P. Cerliani, A.G. Blidner, M.A. Toscano, D.O. Croci, G.A. Rabinovich, Translating the 
'sugar code' into immune and vascular signaling programs, Trends Biochem. Sci. 42 (2017) 
255-273. 
[2] M.T. Elola, F. Ferragut, S.P. Méndez-Huergo, D.O. Croci, C. Bracalente, G.A. 
Rabinovich, Galectins: Multitask signaling molecules linking fibroblast, endothelial and 
immune cell programs in the tumor microenvironment, Cell. Immunol. 333 (2018) 34-45. 
[3] N. Bidon, F. Brichory, S. Hanash, P. Bourguet, L. Dazord, J.P. Le Pennec, Two messenger 
RNAs and five isoforms for Po66-CBP, a galectin-8 homolog in a human lung carcinoma 
cell line, Gene 274 (2001) 253-262. 
[4] Y. Zick, M. Eisenstein, R.A. Goren, Y.R. Hadari, Y. Levy, D. Ronen, Role of galectin-8 
as a modulator of cell adhesion and cell growth, Glycoconj. J. 19 (2004) 517-526. 
[5] Y.R. Hadari, R. Arbel-Goren, Y. Levy, A. Amsterdam, R. Alon, R. Zakut, Y. Zick, 
Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis, J. Cell Sci. 
113 (2000) 2385-2397. 
[6] Y. Levy, R. Arbel-Goren, Y.R. Hadari, S. Eshhar, D. Ronen, E. Elhanany, B. Geiger, Y. 
Zick, Galectin-8 functions as a matricellular modulator of cell adhesion, J. Biol. Chem. 276 
(2001) 31285-31295. 
[7] Y. Levy, D. Ronen, A.D. Bershadsky, Y. Zick, Sustained induction of ERK, protein 
kinase B, and p70 S6 kinase regulates cell spreading and formation of F-actin microspikes 
upon ligation of integrins by galectin-8, a mammalian lectin, J. Biol. Chem. 278 (2003) 
14533-14542. 
[8] R. Arbel-Goren, Y. Levy, D. Ronen, Y. Zick, Cyclin-dependent kinase inhibitors and JNK 
act as molecular switches, regulating the choice between growth arrest and apoptosis 















[9] S.R. Stowell, C.M. Arthur, M. Dias-Baruffi, L.C. Rodrigues, J.P. Gourdine, J. Heimburg-
Molinaro, T. Ju, R.J. Molinaro, C. Rivera-Marrero, B. Xia, D.F. Smith, R.D. Cummings, 
Innate immune lectins kill bacteria expressing blood group antigen, Nat. Med. 16 (2010) 
295-301. 
[10] T.L. Thurston, M.P. Wandel, N. von Muhlinen, A. Foeglein, F. Randow, Galectin 8 
targets damaged vesicles for autophagy to defend cells against bacterial invasion, Nature 
482 (2012) 414-418. 
[11] B. Falcon, J. Noad, H. McMahon, F. Randow, M. Goedert, Galectin-8-mediated selective 
autophagy protects against seeded tau aggregation, J. Biol. Chem. 293 (2018) 2438-2451. 
[12] J.F. Sampson, A. Suryawanshi, W.S. Chen, G.A. Rabinovich, N. Panjwani, Galectin-8 
promotes regulatory T-cell differentiation by modulating IL-2 and TGFbeta signaling, 
Immunol. Cell Biol. 94 (2016) 213-219. 
[13] A. Danguy, S. Rorive, C. Decaestecker, Y. Bronckart, H. Kaltner, Y.R. Hadari, R. 
Goren, Y. Zich, M. Petein, I. Salmon, H.J. Gabius, R. Kiss, Immunohistochemical profile 
of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous 
and adipous origins, and of the nervous system, Histol. Histopathol. 16 (2001) 861-868. 
[14] H. Lahm, S. Andre, A. Hoeflich, J.R. Fischer, B. Sordat, H. Kaltner, E. Wolf, H.J. 
Gabius, Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by 
RT-PCR and its implications for diagnostic and therapeutic procedures, J. Cancer Res. 
Clin. Oncol. 127 (2001) 375-386. 
[15] N. Bidon-Wagner, J.P. Le Pennec, Human galectin-8 isoforms and cancer, Glycoconj. J. 
19 (2004) 557-563. 
[16] M.T. Elola, F. Ferragut, V.M. Cardenas Delgado, L.G. Nugnes, L. Gentilini, D. 
Laderach, M.F. Troncoso, D. Compagno, C. Wolfenstein-Todel, G.A. Rabinovich, 
Expression, localization and function of galectin-8, a tandem-repeat lectin, in human 
tumors, Histol. Histopathol. 29 (2014) 1093-1105. 
[17] Y. Vinik, H. Shatz-Azoulay, Y. Zick, Molecular mechanisms underlying the role of 
galectin-8 as a regulator of cancer growth and metastasis, Trends Glycosci. Glyc. 30 
(2018) SE119-SE128. 
[18] H. Lu, K.L. Knutson, E. Gad, M.L. Disis, The tumor antigen repertoire identified in 
tumor-bearing neu transgenic mice predicts human tumor antigens, Cancer Res. 66 (2006) 
9754-9761. 
[19] H. Barrow, X. Guo, H.H. Wandall, J.W. Pedersen, B. Fu, Q. Zhao, C. Chen, J.M. 















cancer patients and promote cancer cell adhesion to blood vascular endothelium, Clin. 
Cancer Res. 17 (2011) 7035-7046. 
[20] M.M. Fernández, F. Ferragut, V.M. Cardenas Delgado, C. Bracalente, A.I. Bravo, A.J. 
Cagnoni, M. Nunez, L.G. Morosi, H.R. Quinta, M.V. Espelt, M.F. Troncoso, C. 
Wolfenstein-Todel, K.V. Marino, E.L. Malchiodi, G.A. Rabinovich, M.T. Elola, 
Glycosylation-dependent binding of galectin-8 to activated leukocyte cell adhesion 
molecule (ALCAM/CD166) promotes its surface segregation on breast cancer cells, 
Biochim. Biophys. Acta 1860 (2016) 2255-2268. 
[21] C. Oyanadel, C. Holmes, E. Pardo, C. Retamal, R. Shaughnessy, P. Smith, P. Cortes, M. 
Bravo-Zehnder, C. Metz, T. Feuerhake, D. Romero, J.C. Roa, V. Montecinos, A. Soza, A. 
Gonzalez, Galectin-8 induces partial epithelial-mesenchymal transition with invasive 
tumorigenic capabilities involving a FAK/EGFR/proteasome pathway in Madin-Darby 
canine kidney cells, Mol. Biol. Cell 29 (2018) 557-574. 
[22] C. Cárcamo, E. Pardo, C. Oyanadel, M. Bravo-Zehnder, P. Bull, M. Cáceres, J. Martínez, 
L. Massardo, S. Jacobelli, A. González, A. Soza, Galectin-8 binds specific beta1 integrins 
and induces polarized spreading highlighted by asymmetric lamellipodia in Jurkat T cells, 
Exp. Cell Res. 312 (2006) 374-386. 
[23] Y. Levy, S. Auslender, M. Eisenstein, R.R. Vidavski, D. Ronen, A.D. Bershadsky, Y. 
Zick, It depends on the hinge: a structure-functional analysis of galectin-8, a tandem-repeat 
type lectin, Glycobiology 16 (2006) 463-476. 
[24] S. Diskin, W.S. Chen, Z. Cao, S. Gyawali, H. Gong, A. Soza, A. Gonzalez, N. Panjwani, 
Galectin-8 promotes cytoskeletal rearrangement in trabecular meshwork cells through 
activation of Rho signaling, PLoS One 7 (2012) e44400. 
[25] I. Camby, N. Belot, S. Rorive, F. Lefranc, C.A. Maurage, H. Lahm, H. Kaltner, Y. 
Hadari, M.M. Ruchoux, J. Brotchi, Y. Zick, I. Salmon, H.J. Gabius, R. Kiss, Galectins are 
differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic 
astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration, 
Brain Pathol. 11 (2001) 12-26. 
[26] C. Metz, R. Doger, E. Riquelme, P. Cortes, C. Holmes, R. Shaughnessy, C. Oyanadel, C. 
Grabowski, A. Gonzalez, A. Soza, Galectin-8 promotes migration and proliferation and 
prevents apoptosis in U87 glioblastoma cells, Biol. Res. 49 (2016) 33. 
[27] N.E. Reticker-Flynn, D.F. Malta, M.M. Winslow, J.M. Lamar, M.J. Xu, G.H. Underhill, 















identifies cell-extracellular matrix interactions that correlate with metastasis, Nat. 
Commun. 3 (2012) 1122. 
[28] L.N. Cueni, M. Detmar, Galectin-8 interacts with podoplanin and modulates lymphatic 
endothelial cell functions, Exp. Cell Res. 315 (2009) 1715-1723. 
[29] V.M. Delgado, L.G. Nugnes, L.L. Colombo, M.F. Troncoso, M.M. Fernandez, E.L. 
Malchiodi, I. Frahm, D.O. Croci, D. Compagno, G.A. Rabinovich, C. Wolfenstein-Todel, 
M.T. Elola, Modulation of endothelial cell migration and angiogenesis: a novel function 
for the "tandem-repeat" lectin galectin-8, FASEB J. 25 (2011) 242-254. 
[30] M. Friedel, S. Andre, H. Goldschmidt, H.J. Gabius, R. Schwartz-Albiez, Galectin-8 
enhances adhesion of multiple myeloma cells to vascular endothelium and is an adverse 
prognostic factor, Glycobiology 26 (2016) 1048-1058. 
[31] J. Etulain, S. Negrotto, M.V. Tribulatti, D.O. Croci, J. Carabelli, O. Campetella, G.A. 
Rabinovich, M. Schattner, Control of angiogenesis by galectins involves the release of 
platelet-derived proangiogenic factors., PLoS One 9 (2014) e96402. 
[32] Y. Vinik, H. Shatz-Azoulay, A. Vivanti, N. Hever, Y. Levy, R. Karmona, V. Brumfeld, 
S. Baraghithy, M. Attar-Lamdar, S. Boura-Halfon, I. Bab, Y. Zick, The mammalian lectin 
galectin-8 induces RANKL expression, osteoclastogenesis, and bone mass reduction in 
mice, Elife 4 (2015) e05914. 
[33] Y. Vinik, H. Shatz-Azoulay, S. Hiram-Bab, L. Kandel, Y. Gabet, G. Rivkin, Y. Zick, 
Ablation of the mammalian lectin galectin-8 induces bone defects in mice, FASEB J. 32 
(2018) 2366-2380. 
[34] G.W. Swart, P.C. Lunter, J.W. Kilsdonk, L.C. Kempen, Activated leukocyte cell 
adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering 
and cell migration?, Cancer Metastasis Rev. 24 (2005) 223-236. 
[35] A.G. Hansen, G.W. Swart, A. Zijlstra, ALCAM: basis sequence: mouse, AFCS Nat. Mol. 
Pages 2011 (2011). 
[36] K.E. Hebron, E.Y. Li, S.A. Arnold Egloff, A.K. von Lersner, C. Taylor, J. Houkes, D.K. 
Flaherty, A. Eskaros, T.P. Stricker, A. Zijlstra, Alternative splicing of ALCAM enables 
tunable regulation of cell-cell adhesion through differential proteolysis., Sci. Rep. 8 (2018) 
3208. 
[37] A.G. Hansen, S.A. Arnold, M. Jiang, T.D. Palmer, T. Ketova, A. Merkel, M. Pickup, S. 
Samaras, Y. Shyr, H.L. Moses, S.W. Hayward, J.A. Sterling, A. Zijlstra, ALCAM/CD166 
is a TGF-beta-responsive marker and functional regulator of prostate cancer metastasis to 















[38] K. Fujiwara, K. Ohuchida, M. Sada, K. Horioka, C.D. Ulrich, K. Shindo, T. Ohtsuka, S. 
Takahata, K. Mizumoto, Y. Oda, M. Tanaka, CD166/ALCAM expression is characteristic 
of tumorigenicity and invasive and migratory activities of pancreatic cancer cells, PLoS 
One 9 (2014) e107247. 
[39] L. Ma, J. Wang, J. Lin, Q. Pan, Y. Yu, F. Sun, Cluster of differentiation 166 (CD166) 
regulated by phosphatidylinositide 3-Kinase (PI3K)/AKT signaling to exert its anti-
apoptotic role via yes-associated protein (YAP) in liver cancer, J. Biol. Chem. 289 (2014) 
6921-6933. 
[40] W. Yu, J. Wang, L. Ma, X. Tang, Y. Qiao, Q. Pan, Y. Yu, F. Sun, CD166 plays a pro-
carcinogenic role in liver cancer cells via inhibition of FOXO proteins through AKT, 
Oncol. Rep. 32 (2014) 677-683. 
[41] X. Tang, X. Chen, Y. Xu, Y. Qiao, X. Zhang, Y. Wang, Y. Guan, F. Sun, J. Wang, 
CD166 positively regulates MCAM via inhibition to ubiquitin E3 ligases Smurf1 and 
betaTrCP through PI3K/AKT and c-Raf/MEK/ERK signaling in Bel-7402 hepatocellular 
carcinoma cells, Cell. Signal. 27 (2015) 1694-1702. 
[42] L. Devis, C.P. Moiola, N. Masia, E. Martinez-Garcia, M. Santacana, T.V. Stirbat, F. 
Brochard-Wyart, A. Garcia, F. Alameda, S. Cabrera, J. Palacios, G. Moreno-Bueno, M. 
Abal, W. Thomas, S. Dufour, X. Matias-Guiu, A. Santamaria, J. Reventos, A. Gil-Moreno, 
E. Colas, Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence 
and promotes cell migration, invasion, and metastasis in early-stage endometrioid 
endometrial cancer, J. Pathol. 241 (2017) 475-487. 
[43] J. Hirabayashi, T. Hashidate, Y. Arata, N. Nishi, T. Nakamura, M. Hirashima, T. 
Urashima, T. Oka, M. Futai, W.E. Muller, F. Yagi, K. Kasai, Oligosaccharide specificity 
of galectins: a search by frontal affinity chromatography, Biochim. Biophys. Acta 1572 
(2002) 232-254. 
[44] H. Ideo, A. Seko, I. Ishizuka, K. Yamashita, The N-terminal carbohydrate recognition 
domain of galectin-8 recognizes specific glycosphingolipids with high affinity, 
Glycobiology 13 (2003) 713-723. 
[45] S. Carlsson, C.T. Oberg, M.C. Carlsson, A. Sundin, U.J. Nilsson, D. Smith, R.D. 
Cummings, J. Almkvist, A. Karlsson, H. Leffler, Affinity of galectin-8 and its 
carbohydrate recognition domains for ligands in solution and at the cell surface, 















[46] H. Ideo, T. Matsuzaka, T. Nonaka, A. Seko, K. Yamashita, Galectin-8-N-domain 
recognition mechanism for sialylated and sulfated glycans, J. Biol. Chem. 286 (2011) 
11346-11355. 
[47] H. Yoshida, S. Yamashita, M. Teraoka, A. Itoh, S. Nakakita, N. Nishi, S. Kamitori, X-
ray structure of a protease-resistant mutant form of human galectin-8 with two 
carbohydrate recognition domains, FEBS J. 279 (2012) 3937-3951. 
[48] P.H. Jensen, N.G. Karlsson, D. Kolarich, N.H. Packer, Structural analysis of N- and O-
glycans released from glycoproteins, Nat. Protoc. 7 (2012) 1299-1310. 
[49] L. Royle, R.A. Dwek, P.M. Rudd, Determining the structure of oligosaccharides N- and 
O-linked to glycoproteins, in Curr. Protoc. Protein Sci., 2006, pp. 1-45. 
[50] R. Saldova, A. Asadi Shehni, V.D. Haakensen, I. Steinfeld, M. Hilliard, I. Kifer, A. 
Helland, Z. Yakhini, A.L. Børresen-Dale, P.M. Rudd, Association of N-Glycosylation with 
breast carcinoma and systemic features using High-Resolution Quantitative UPLC, J. 
Proteome Res. 13 (2014) 2314-2327. 
[51] K. Mariño, J. Bones, J.J. Kattla, P.M. Rudd, A systematic approach to protein 
glycosylation analysis: a path through the maze, Nat. Chem. Biol. 6 (2010) 713-723. 
[52] M.T. Elola, C. Wolfenstein-Todel, M.F. Troncoso, G.R. Vasta, G.A. Rabinovich, 
Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and 
survival, Cell Mol. Life Sci. 64 (2007) 1679-1700. 
[53] S. Hein, V. Muller, N. Kohler, H. Wikman, S. Krenkel, T. Streichert, M. Schweizer, S. 
Riethdorf, V. Assmann, M. Ihnen, K. Beck, R. Issa, F. Janicke, K. Pantel, K. Milde-
Langosch, Biologic role of activated leukocyte cell adhesion molecule overexpression in 
breast cancer cell lines and clinical tumor tissue, Breast Cancer Res. Treat. 129 (2011) 
347-360. 
[54] L.D. Gentilini, F.M. Jaworski, C. Tiraboschi, I.G. Perez, M.L. Kotler, A. Chauchereau, 
D.J. Laderach, D. Compagno, Stable and high expression of Galectin-8 tightly controls 
metastatic progression of prostate cancer, Oncotarget 8 (2017) 44654-44668. 
[55] A. Jezierska, W. Matysiak, T. Motyl, ALCAM/CD166 protects breast cancer cells 
against apoptosis and autophagy, Med. Sci. Monit. 12 (2006) BR263-273. 
[56] A.K. Ludwig, M. Michalak, N. Shilova, S. Andre, H. Kaltner, N.V. Bovin, J. Kopitz, 
H.J. Gabius, Studying the structural significance of galectin design by playing a modular 
puzzle: homodimer generation from human tandem-repeat-type (heterodimeric) galectin-8 















[57] S.K. Patnaik, B. Potvin, S. Carlsson, D. Sturm, H. Leffler, P. Stanley, Complex N-
glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells, 
Glycobiology 16 (2006) 305-317. 
[58] T.K. Dam, F.C. Brewer, Maintenance of cell surface glycan density by lectin-glycan 
interactions: A homeostatic and innate immune regulatory mechanism, Glycobiology 20 
(2010) 1061-1064. 
[59] J.W. Dennis, C.F. Brewer, Density-dependent lectin-glycan interactions as a paradigm 
for conditional regulation by posttranslational modifications, Moll. Cell. Proteomics 12 
(2013) 913-920. 
[60] Y. Yuan, L. Wu, S. Shen, S. Wu, M.M. Burdick, Effect of alpha 2,6 sialylation on 
integrin-mediated adhesion of breast cancer cells to fibronectin and collagen IV, Life Sci. 
149 (2016) 138-145. 
[61] J. Lu, T. Isaji, S. Im, T. Fukuda, A. Kameyama, J. Gu, Expression of N-
acetylglucosaminyltransferase III suppresses α2,3-sialylation, and its distinctive functions 
in cell migration are attributed to α2,6-sialylation levels, J. Biol. Chem. 291 (2016) 5708-
5720. 
[62] T. Isaji, S. Im, A. Kameyama, Y. Wang, T. Fukuda, J. Gu, A complex between 
phosphatidylinositol 4 kinase IIα and integrin α3β1 is required for N-glycan sialylation in 
cancer cells, J. Biol. Chem. (2019) doi: 10.1074/jbc.RA1118.005208. 
[63] J.M. Lebert, R. Lester, E. Powell, M. Seal, J. McCarthy, Advances in the systemic 
treatment of triple-negative breast cancer, Curr. Oncol. 25 (2018) S142-S150. 
[64] A. Varki, R.D. Cummings, M. Aebi, N.H. Packer, P.H. Seeberger, J.D. Esko, P. Stanley, 
G. Hart, A. Darvill, T. Kinoshita, J.J. Prestegard, R.L. Schnaar, H.H. Freeze, J.D. Marth, 
C.R. Bertozzi, M.E. Etzler, M. Frank, J.F.G. Vliegenthart, T. Lütteke, S. Perez, E. Bolton, 
P. Rudd, J. Paulson, M. Kanehisa, P. Toukach, K.F. Aoki-Kinoshita, A. Dell, H. 
Narimatsu, W. York, N. Taniguchi, S. Kornfeld, Symbol nomenclature for graphical 



















Figure 1. Silencing ALCAM in MDA-MB-231 breast cancer cells decreases cell adhesion 
onto Gal-8-coated surfaces in a glycan-dependent manner. Western blot analysis of Gal-8 (A, 
upper panel) and ALCAM (B, upper panel) expression in whole lysates from MDA-MB-231, 
mock-transduced MDA-MB-231 (MDA-shControl), MDA-MB-231-shALCAM (MDA-
shALCAM), MDA-MB-231-shGal-8 (MDA-shGal8), and MDA-MB-231-shALCAM-shGal-8 
(MDA-shALCAM-shGal8) cells. Lysates were run in parallel in the same 10% gel in SDS-
PAGE, and then transferred onto PVDF membranes. Blots were probed with primary antibodies, 
followed by the incubation with the appropriate secondary antibody conjugated to HRP and 
detection by chemiluminiscence. The bar graphs show Gal-8 (A, lower panel) and ALCAM (B, 
lower panel) protein expression in densitometric analysis; β-actin was used to normalize protein 
loading. Data were analyzed by one-way ANOVA with Tukey post-test (n=7). Asterisks (***) 
denote a statistically significant difference with p<0.001. (C) Dose-response curves of cell 
adhesion assays onto full-length rGal-8 (0.25-3 M) or BSA as substrates, obtained by incubating 
MDA-MB-231, MDA-shControl, MDA-shGal8, MDA-shALCAM, and MDA-shALCAM-
shGal8 cells (2 x 10
4
 cells/well) during 1 h. A: absorbance at 595 nm. Data were analyzed by 
two-way ANOVA with Tukey post-test (n=5). *p<0.05. (D) Indirect immunofluorescence 
staining for cell surface expression of endogenous ALCAM in non-permeabilized MDA-MB-231, 
MDA-shControl, MDA-shALCAM and MDA-shALCAM-shGal8 cells, as evaluated by confocal 
microscopy. Endogenous ALCAM was developed with an unconjugated anti-ALCAM 
monoclonal antibody followed by an Alexa 555-conjugated secondary antibody (red, left panel). 
Merged images of DAPI staining (nuclei, blue) and phase contrast are also shown (right panel). 
Each experiment was performed three times with reproducible results. Scale bars: 10 μm. (E) Cell 
adhesion assays onto full-length rGal-8 (2 M) as a substrate were performed by incubating 
MDA-MB-231, MDA-shControl, MDA-shGal8, MDA-shALCAM, and MDA-shALCAM-
shGal8 cells (2 x 10
4
 cells/well) during 1 h in the presence of lactose (100 mM), a disaccharide 
which binds to Gal-8 CRDs, or the unrelated disaccharide sucrose (100 mM). A: absorbance at 
595 nm. Data were analyzed by two-way ANOVA with Bonferroni post-test (n=4). *p<0.05. 
Values in Fig. 1 A,B,C,E are presented as mean values ± S.E.M. with differences at p≤0.05 
















Figure 2. Silencing ALCAM in MDA-MB-231 breast cancer cells decreases cell migration 
onto Gal-8-coated surfaces in a glycan-dependent fashion. (A) Wound healing assays were 
performed as described in Materials and Methods, onto surfaces without or with full-length rGal-
8 (2 M) coating. To evaluate wound closure, MDA-MB-231, MDA-shControl, MDA-shGal8, 
MDA-shALCAM, and MDA-shALCAM-shGal8 cells were incubated with DMEM without FBS 
for 20 h at 37 ºC. Image J software was used to determine the whole area of the wound at each 
incubation time. Values represent the mean ± S.E.M. of the percentage of wound closure at 20 h 
versus 0 h. Data were analyzed by two-way ANOVA with Bonferroni post-test (n=7). 
***p<0.001; **p<0.01. (B) Cell migration onto surfaces without (left panel) or with full-length 
rGal-8 (2 M) coating (right panel) was determined by wound closure and photographed at 0 and 
20 h for MDA-MB-231, MDA-shControl, MDA-shGal8, MDA-shALCAM, and MDA-
shALCAM-shGal8 cells. Representative photographs are shown. Scale bars: 0.1 mm. (C) Cell 
migration onto full-length rGal-8 (2 M) as a substrate was quantified in the presence of 100 mM 
lactose or 100 mM sucrose. Values represent the mean ± S.E.M., and data were analyzed by two-
way ANOVA with Bonferroni post-test (n=7). ***p<0.001; **p<0.01; *p<0.05. (D) Effects of 
lactose (100 mM; left panel) and sucrose (100 mM; right panel) on cell migration onto 
immobilized rGal-8 are shown in representative photographs. Scale bars: 0.1 mm. n.s.: 
differences were not statistically significant. 
 
Figure 3. Silencing of Gal-8 or ALCAM in MDA-MB-231 breast cancer cells decreases cell-
cell adhesion. (A) MDA-MB-231, MDA-shControl, MDA-shGal8, MDA-shALCAM, and 
MDA-shALCAM-shGal8 single-cell suspensions were incubated in FBS-free DMEM with gentle 
rotation at 37 °C for 1 h. Each sample was loaded onto different wells of 96-well plates to be 
photographed, and the number of free cells was counted at 0 and 1 h in five fields per sample. 
Aggregation was calculated as the percentages of free cells incubated in the absence of exogenous 
rGal-8. Each assay was performed in triplicates, and values represent the mean ± S.E.M. Data 
were analyzed by one-way ANOVA with Tukey post-test (n=4). *p<0.05. (B) Representative 
photographs of MDA-MB-231, MDA-shControl, MDA-shGal8, MDA-shALCAM, and MDA-
shALCAM-shGal8 cell aggregation performed without adding exogenous rGal-8. Each inset 

















Figure 4. ALCAM silencing inhibits cell proliferation in MDA-MB-231 breast cancer cells. 
(A) MDA-MB-231, MDA-shControl, MDA-shGal8, MDA-shALCAM, and MDA-shALCAM-
shGal8 cell proliferation was evaluated in MTT assays. Formazan crystals formed in viable cells 
were dissolved in dimethyl sulfoxide, and absorbance was measured at 595 nm. Cell proliferation 
was measured after 0, 24, 48, 72 and 96 h as described in Materials and Methods. At 96 h, both 
MDA-shALCAM (p0.05; p0.01) and MDA-shALCAM-shGal8 (p0.001; p0.001) cells 
showed decreased proliferation compared to control MDA-MB-231 and MDA-shControl cells, 
respectively. MDA-shALCAM (p0.01) and MDA-shALCAM-shGal8 (p0.001) cells also 
showed decreased proliferation compared to MDA-shGal8 cells. Data were analyzed by two-way 
ANOVA with Holm-Sídák post-test (n=6). ***p<0.001; **p<0.01; *p<0.05. (B) Colony 
formation ability of single cells was evaluated. Cells were incubated for 10 days at 37 °C. Finally, 
cells were fixed in paraformaldehyde and stained with crystal violet, and colonies were 
photographed and quantified. Data were analyzed by one-way ANOVA with Tukey post-test 
(n=7). ***p<0.001. (C) Spheroid-formation assay was performed by seeding MDA-MB-231, 
MDA-shControl, MDA-shGal8, MDA-shALCAM, and MDA-shALCAM-shGal8 cells onto 
matrigel. Spheroids were photographed after 3, 7 and 10 days of incubation (left panel). Spheroid 
volumes versus the incubation time were also plotted (right panel). Data were analyzed by two-
way ANOVA with Bonferroni post-test (n=3). ***p<0.001; **p<0.01. Scale bars (3, 7, 10 days): 
50 µm. Values in Fig. 4 A-C are presented as mean ± S.E.M. n.s.: differences were not 
statistically significant. 
 
Figure 5. Dual targeting of ALCAM and Gal-8 decreases primary tumor size in a murine 
model of triple negative breast cancer. (A) MDA-MB-231, MDA-shControl, MDA-shGal8, 
MDA-shALCAM, and MDA-shALCAM-shGal8 human breast cancer cells were subcutaneously 
inoculated in nude mice in the presence of matrigel. Tumor volume was evaluated 2-3 times a 
week. Gal-8 and ALCAM silencing significantly delayed the growth of primary tumors. Control 
mice were euthanized because of ethical reasons at day 56 post-inoculum as well as mice 
inoculated with MDA-shGal8 cells for comparison. Mice injected with MDA-shALCAM and 
MDA-shALCAM-shGal8 cells (which tumors were considerably small at day 56 post-inoculum) 
were kept alive until 98 days post-inoculum. At day 98, tumors generated by MDA-shALCAM-
shGal8 cells proved to be smaller than those generated by MDA-shALCAM cells. **p<0.01; 
*p<0.05. Values represent the mean ± S.E.M. from two independent experiments, and were 
analyzed by Chi-square test. (B) Photographs of representative primary tumors derived from 















shGal8 cells were taken at 56 days post-inoculum. Scale bars: 1 cm. (C) Western blot experiments 
showing significantly decreased Gal-8 protein levels at day 56 post-inoculum (p0.01) in tumors 
derived from MDA-shGal8 cells as compared to those generated by control cells, an effect that 
was also statistically significant in tumors derived from MDA-shALCAM-shGal8 cells at day 98 
post-inoculum as compared to those generated by control cells (p0.05) (left panel). ALCAM 
expression levels were significantly reduced (p0.001) in tumors generated by ALCAM-silenced 
(MDA-shALCAM and MDA-shALCAM-shGal8) cells at day 98 as compared to those generated 
by control and MDA-shGal8 cells at day 56 (right panel). Values represent the mean ± S.E.M., 
and data were analyzed by one-way ANOVA with Bonferroni post-test (n=4). ***p<0.001; 
**p<0.01; *p<0.05. (D) Representative photographs of haematoxylin and eosin staining 
performed in tumor-draining lymph node sections. A lymph node section without metastasis (left 
panel) from mice inoculated with control MDA-MB-231 cells is shown (magnification: x5). A 
lymph node with metastasis (central panel) from mice inoculated with control MDA-MB-231 
cells is shown (magnification: x5). The two insets (magnification: x40) display metastatic foci 
(a), and lymphatic vessel invasion by tumor cells (b). Lymph node with micrometastasis (right 
panel) derived from inoculated MDA-shGal8 cells is shown (magnification: x5; inset 
magnification: x40). Scale bars: 500 µm. n.s.: differences were not statistically significant. 
 
Figure 6. N-glycosylation profile of ALCAM purified from MDA-MB-231 cells. (A) N-
Glycan analysis by hydrophilic interaction liquid chromatography (HILIC). Released N-glycans 
were labeled with 2AB, and the scale of glucose units (GU) is based on the elution of the 2AB 
labeled glucose ladder. Glycans were represented according to the symbol nomenclature proposed 
by [64]. Only the major species have been shown (a detailed N-glycan structural characterization 
is presented in supplemental Table S1). N-glycans are coloured according to their structure, i.e. 
red for neutral (N), blue for monosialylated (S1), green for disialylated (S2), purple for 
trisialylated (S3) and orange for tetrasialylated (S4) structures. (B) Relative abundance of the 
different N-glycan groups (neutral, mono-, di-, tri- and tetra-sialylated) described in (A). ALCAM 
N-glycoprofiling shows high abundance of non-sialylated glycans and relatively high proportions 
of di- and trisialylated glycans. (C) Relative abundance of high mannose (HM) and complex N-
glycans. Complex glycans are divided based on their antennarity (A1, monoantennary; A2, 
biantennary; A3 triantennary and A4, tetraantennary), showing mostly complex N-glycans with 
major proportions of di- and triantennary structures. (D) Sialic acid linkage in complex N-















proportion of α(2-6) sialylation. (E) Relative abundance of MDA-MB-231 endogenous ALCAM 
N-glycans permissive and non-permissive for Gal-8 binding. (F) Relative abundance of MDA-
MB-231 endogenous ALCAM N-glycans permissive and non-permissive for Gal-8 binding, after 
treatment with α(2-3,6,8,9) neuraminidase A. 
 
Figure 7. Cell surface sialylation influences MDA-MB-231 breast cancer cell interaction 
with immobilized Gal-8 and compromise cell adhesion. (A) Flow cytometry analysis of the 
glycophenotype of MDA-MB-231 cells treated with α(2-3,6,8,9) neuraminidase A (green), α(2-3) 
neuraminidase (blue) or without any glycosidase (grey), detected with biotinylated plant lectins 
(MAL II or SNA) followed by phycoerythrin-conjugated streptavidin. Negative controls were 
performed by treating cells with phycoerythrin-conjugated streptavidin alone, without any plant 
lectin (red). PE: phycoerythrin. Normalized number of events plotted: 10,000. (B) Cell adhesion 
assays were performed in 96-well tissue culture plates coated with full-length rGal-8 (5 M, to 
improve method sensitivity) or BSA. MDA-MB-231, MDA-shControl, MDA-shGal8, MDA-
shALCAM, and MDA-shALCAM-shGal8 cells (3 x 10
4
 cells/well) were treated with α(2-3,6,8,9) 
neuraminidase A (green) and α(2-3) neuraminidase (blue) and compared with each untreated cell 
line (grey), after incubating for 2 h onto rGal-8-coated surfaces. Neuraminidase A treatment 
increased cell adhesion onto rGal-8 as compared to untreated cells for each ALCAM
+
 cell line 
(MDA-MB-231: p0.01; MDA-shControl: p0.01; MDA-shGal8: p0.05). Treatment with α(2-3) 
neuraminidase also increased cell adhesion onto rGal-8 in MDA-MB-231, MDA-shControl and 
MDA-shGal8cells (p0.05) as compared to each untreated cell line. Each treatment for ALCAM
+ 
cell lines increased cell adhesion (p0.001) onto rGal-8 as compared to the same treatment in 
ALCAM-silenced cell lines. A: Absorbance at 595 nm. Data in Fig. 7 B are presented as mean 
values ± S.E.M., and were analyzed by two-way ANOVA with Sídák post-test (n=3). 
***p<0.001; **p<0.01; *p<0.05. n.s.: differences were not statistically significant. 
 
Appendix A. Supplementary data 
 
Figure S1. Intercellular interactions in control MDA-MB-231 cells are promoted by Gal-8 
in a dose- and glycan-dependent manner. Aggregation in control MDA-MB-231 and MDA-
shControl cells was performed by incubating the cells with increasing concentrations of 
exogenous soluble rGal-8 (1-5 µM). Lactose (100 mM) was used as a saccharide inhibitor. Unless 
indicated, statistical significance was calculated compared to cells without lectin (rGal-8: 0 µM) 















S.E.M., and were analyzed by two-way ANOVA with Tukey post-test (n=5). n.s.: differences 
were not statistically significant. 
 
Table S1. Detailed structural characterization of N-glycan species present in ALCAM from 
MDA-MB-231 cells. Structure abbreviations: all N-glycans have two core GlcNAcs; F at the start 
of the abbreviation indicates a core fucose (CF) α(1-6)-linked to the inner GlcNAc; Mx, number 
(x) of mannose on core GlcNAcs; Ax, number of antennae (GlcNAc) on trimannosyl core; A2, 
biantennary with both GlcNAcs as β(1-2)-linked; A3, triantennary with a GlcNAc linked β(1-2) 
to both mannose and the third GlcNAc linked β(1-4) to the α(1-3) linked mannose; A4, GlcNAcs 
linked as A3 with additional GlcNAc β(1-6) linked to α(1-6) mannose; B, bisecting GlcNAc 
linked β(1-4) to β(1-3) mannose; Gx, number (x) of β(1-4) linked galactose on antenna; Sx, 
number (x) of sialic acids linked to galactose. Dx: isoforms with different high mannose (HM)-
binding. Peaks calculated into specific features are highlighted in grey. The N-glycans shown are 
coloured according to their sialylation, i.e. red for neutral (N) N-glycans, blue for monosialylated 
(S1) structures, green for disialylated (S2) structures, purple for trisialylated (S3) structures and 
orange for tetrasialylated (S4) structures. Glycans were represented according to the symbol 

















 ALCAM silencing decreases in vitro cell adhesion and migration onto Gal-8. 
 Surface ALCAM establishes glycan-dependent cell interactions with Gal-8. 
 Either Gal-8 or ALCAM silencing attenuates cell-cell aggregation. 
 In mouse xenografts, Gal-8 and ALCAM silencing synergistically slow down tumor 
growth. 
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